A Delaware federal judge has allowed Amgen Inc. to pursue enhanced damages in its patent infringement dispute with a rival drugmaker, the latest development to a case with billions of dollars on the line.

U.S. District Judge Sue L. Robinson of the District of Delaware on Wednesday granted Amgen’s motion to amend a Jan. 3 memorandum opinion to include an award of supplemental damages, as well as enhanced damages on top of those.